Loading…
Apimeds Pharmaceuticals US, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in APUS.
▼ -58.6% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| FBLGFibroBiologics, Inc. | $1.44 | — | 1.9x | — | -660.08% | $9.59M |
| XBIOXenetic Biosciences, Inc. | $3.98 | — | 1.2x | — | -47.04% | $9.33M |
| IMRNImmuron Ltd | $1.15 | — | 1.0x | — | -39.68% | $9.28M |
| AMSAmerican Shared Hospital Services | $1.47 |
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Company description provided by Yahoo Finance.
| — |
| 0.4x |
| — |
| -12.06% |
| $9.78M |
| TRAWTraws Pharma, Inc. | $0.59 | — | 5.3x | — | -433.36% | $9.07M |
| MBAIMBody AI Ltd. | $6.58 | 1.4x | 13.4x | — | — | $9.05M |